drugset / Trial / NCT06080880
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
RandomizedParallel-groupOpen-labelPrevention
Summary
The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2025-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ondansetron | Other / unclassified | 24 mg | Oral |
| Background | Aprepitant | Other / unclassified | 125 mg | Oral |
| Background | Dexamethasone | Small molecule | 10 mg | Intravenous |